Diabetes Mellitus and Cancer
DOI:
https://doi.org/10.12970/2310-9971.2013.01.02.2Keywords:
Diabetes mellitus, hyperinsulinemia, metformin, cancer.Abstract
Diabetes and cancer are frequent diseases with important impact on human health all the world. Last epidemiologic studies suggests that patients with diabetes are at significantly higher risk for many forms of cancer. Type 2 diabetes and cancer share many risk factors. Increased insulin-like growth factor I (IGF-I) and reactive oxygen species can rol play in carcinogenesis. The systemic chronical inflammation which can result in a protumorigenic conditions. Hyperinsulinemia increases the risk of cancer in healthy people and it can partly explain obesity-cancer risk. The other point of view very important and difficult issue the medical treatment and dietary of diabetic patients with cancer.References
[1] Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009; 16: 1103- 23. http://dx.doi.org/10.1677/ERC-09-0087
[2] Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci 2013; 104: 9-14. http://dx.doi.org/10.1111/cas.12043
[3] Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620. http://dx.doi.org/10.1093/jnci/91.7.620
[4] Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, et al. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999; 83: 15-17. http://dx.doi.org/10.1002/(SICI)1097- 0215(19990924)83:13.0.CO;2-Y
[5] Palmqvist R, Hallmans G, Rinaldi S, Biessey C, Stenling R, Riboli E, Kaaks R. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 2002; 642. http://dx.doi.org/10.1136/gut.50.5.642
[6] Jones J, Clemmons D. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3.
[7] Underwood LE, Thissen JP, Lemozy S, Ketelslegers JM, Clemmons DR. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 1994; 42: 145. http://dx.doi.org/10.1159/000184187
[8] Hou WK, Xu YX, Yu T, Zhang L, Zhang WW, Fu CL, et al. Adipocytokines and breast cancer risk. Chin Med J (Engl) 2007; 120: 1592-96.
[9] Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006; 237: 109-14. http://dx.doi.org/10.1016/j.canlet.2005.05.047
[10] Shahar S, Salleh RM, Ghazali AR, Koon PB, Mohamud WN. Roles of adiposity, lifetime physical activity and serum adiponectin in occurrence of breast cancer among Malaysian women in Klang Valley. Asian Pac J Cancer Prev 2010; 11: 61-66.
[11] Oh SW, Park CY, Lee ES, Yoon YS, Lee ES, Park SS, et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res 2011; 13: 34. http://dx.doi.org/10.1186/bcr2856
[12] Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, et al. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002; 123(4): 1191-204. http://dx.doi.org/10.1053/gast.2002.36023
[13] Donohoe CL, Pidgeon GP, Lysaghtand J, Reynolds JV. Obesity and gastrointestinal cancer. Br J Surg 2010; 97: 628- 42. http://dx.doi.org/10.1002/bjs.7079
[14] Wei EK, Giovannuchi E. Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J Natl Cancer Instit 2005; 9: 22.
[15] Gallagher EJ, LeRoith D. Review The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metabol 2010; 21: 610-18. http://dx.doi.org/10.1016/j.tem.2010.06.007
[16] Delamaire M, Maugendre D, Moreno M, et al. Impaired leucocyte functions in diabetic patients. Diabetic Med 1997; 14: 29-34. http://dx.doi.org/10.1002/(SICI)1096- 9136(199701)14:13.0.CO;2-V
[17] Insulin Administration. American Diabetes Association: Clinical Practice Recommendations 2004. Diab Care 2004; 24(Suppl 1): 106-10.
[18] De Censi A, Puntoni M, Goodwin P, et al. Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis Cancer Prev Res 2010; 3: 1451-61.
[19] Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-73. http://dx.doi.org/10.1158/0008-5472.CAN-06-1500
[20] Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycindependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804-12. http://dx.doi.org/10.1158/0008-5472.CAN-07-2310
[21] Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32: 1620-5. http://dx.doi.org/10.2337/dc08-2175
[22] Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based casecontrol study. Cancer Causes Control 2009; 20: 1617-22. http://dx.doi.org/10.1007/s10552-009-9407-y
[23] Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116: 1938-46. http://dx.doi.org/10.1002/cncr.24982
[24] Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007; 132: 2208-25. http://dx.doi.org/10.1053/j.gastro.2007.03.050
[25] Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007; 100: 328-41. http://dx.doi.org/10.1161/01.RES.0000256090.42690.05
[26] Palacios OM, Carmona JJ, Michan S, et al. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1 in skeletal muscle. Aging (Albany NY) 2009; 1: 771-83.
[27] Tzatsos A, Kandror KV. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling viaraptor-dependen tm TORmediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 2006; 26: 63-76. http://dx.doi.org/10.1128/MCB.26.1.63-76.2006
[28] Monami M, Luzzi C, Lamanna C, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006; 22: 477-82. http://dx.doi.org/10.1002/dmrr.642
[29] Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 yearr and omised, open-label study. Diabetologia 2009; 52: 1971-3. http://dx.doi.org/10.1007/s00125-009-1452-2
[30] Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-44. http://dx.doi.org/10.1007/s00125-009-1418-4
[31] Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and shortterm incidence of malignancies—a population-based followup study in Sweden. Diabetologia 2009; 52: 1745-54. http://dx.doi.org/10.1007/s00125-009-1444-2
[32] Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330: 1304-305. http://dx.doi.org/10.1136/bmj.38415.708634.F7
[33] Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3: 1451-61. http://dx.doi.org/10.1158/1940-6207.CAPR-10-0157
